Literature DB >> 11586555

Escherichia coli O157:H7.

P I Tarr1, M A Neill.   

Abstract

E. coli O157:H7 can cause potentially lethal illness in hosts of all ages. These patients often are evaluated and treated by gastroenterologists. The treating physician should administer adequate hydration, usually parenterally, and avoid the use of antibiotics and antimotility agents. The physician needs to notify immediately the appropriate public health authorities of the diagnosis and to ensure that the isolate is recovered by the microbiologist and forwarded for molecular linkage analyses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11586555     DOI: 10.1016/s0889-8553(05)70208-9

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  12 in total

1.  Shiga toxin antigen detection should not replace sorbitol MacConkey agar screening of stool specimens.

Authors:  Eileen J Klein; Jennifer R Stapp; Marguerite A Neill; John M Besser; Michael T Osterholm; Phillip I Tarr
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

2.  Cytolethal distending toxin from Shiga toxin-producing Escherichia coli O157 causes irreversible G2/M arrest, inhibition of proliferation, and death of human endothelial cells.

Authors:  Martina Bielaszewska; Bhanu Sinha; Thorsten Kuczius; Helge Karch
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 3.  Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulence.

Authors:  Dakshina M Jandhyala; Vijay Vanguri; Erik J Boll; Yushuan Lai; Beth A McCormick; John M Leong
Journal:  Infect Dis Clin North Am       Date:  2013-07-24       Impact factor: 5.982

4.  Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells.

Authors:  D E Akiyoshi; C M Rich; S O'Sullivan-Murphy; L Richard; J Dilo; A Donohue-Rolfe; A S Sheoran; S Chapman-Bonofiglio; S Tzipori
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Phenotypic and molecular analysis of tellurite resistance among enterohemorrhagic Escherichia coli O157:H7 and sorbitol-fermenting O157:NM clinical isolates.

Authors:  Martina Bielaszewska; Phillip I Tarr; Helge Karch; Wenlan Zhang; Werner Mathys
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

6.  Distribution of the urease gene cluster among and urease activities of enterohemorrhagic Escherichia coli O157 isolates from humans.

Authors:  Alexander W Friedrich; Robin Köck; Martina Bielaszewska; Wenlan Zhang; Helge Karch; Werner Mathys
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

Review 7.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 8.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

9.  Bacterial colitis.

Authors:  Harry T Papaconstantinou; J Scott Thomas
Journal:  Clin Colon Rectal Surg       Date:  2007-02

Review 10.  Management of diarrhea-associated hemolytic uremic syndrome in children.

Authors:  Kazumoto Iijima; Ichiro Kamioka; Kandai Nozu
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.